Cargando…

Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes

Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are...

Descripción completa

Detalles Bibliográficos
Autores principales: Nallicheri, Armaan, Mahoney, Katherine M, Gutow, Hanna A, Bellini, Natalie, Isaacs, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354504/
https://www.ncbi.nlm.nih.gov/pubmed/35949359
http://dx.doi.org/10.17925/EE.2022.18.1.27
_version_ 1784763086956134400
author Nallicheri, Armaan
Mahoney, Katherine M
Gutow, Hanna A
Bellini, Natalie
Isaacs, Diana
author_facet Nallicheri, Armaan
Mahoney, Katherine M
Gutow, Hanna A
Bellini, Natalie
Isaacs, Diana
author_sort Nallicheri, Armaan
collection PubMed
description Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care.
format Online
Article
Text
id pubmed-9354504
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Touch Medical Media
record_format MEDLINE/PubMed
spelling pubmed-93545042022-08-09 Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes Nallicheri, Armaan Mahoney, Katherine M Gutow, Hanna A Bellini, Natalie Isaacs, Diana touchREV Endocrinol Diabetes Automated insulin delivery (AID) systems play an important role in the management of type 1 diabetes mellitus (T1DM). These systems include three components: a continuous glucose monitor (CGM), an insulin pump and an algorithm that adjusts the pump based on the CGM sensor glucose readings. They are not fully automated and still require the user to administer bolus insulin doses for food. Some AID systems have automatic correction boluses, while others only have automatic basal or background insulin adjustments. As CGM has become more accurate and the technology has evolved, AID systems have demonstrated improved glycaemic outcomes. The clinical evaluation of AID systems in randomized controlled trials and real-world studies have shown their utility in helping glycaemic management. In this review, we compare AID systems that are commercially available in the US and summarize the literature, with a special focus on time in range in T1DM. The review also discusses new AID systems on the horizon and explores considerations for personalized care. Touch Medical Media 2022-06 2022-05-20 /pmc/articles/PMC9354504/ /pubmed/35949359 http://dx.doi.org/10.17925/EE.2022.18.1.27 Text en © Touch Medical Media 2022 ali:free_to_read www.copyright.com (http://www.copyright.com) Review Process: Double-blind peer review. Compliance with ethics: This study involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors. Data availability: Data sharing is not applicable to this article as no datasets were generated or analysed during the writing of this study. Authorship: The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published. https://creativecommons.org/licenses/by/3.0/Access: This article is freely accessible at touchCARDIO.com (http://touchCARDIO.com) © Touch Medical Media 2022.
spellingShingle Diabetes
Nallicheri, Armaan
Mahoney, Katherine M
Gutow, Hanna A
Bellini, Natalie
Isaacs, Diana
Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
title Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
title_full Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
title_fullStr Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
title_full_unstemmed Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
title_short Review of Automated Insulin Delivery Systems for Type 1 Diabetes and Associated Time in Range Outcomes
title_sort review of automated insulin delivery systems for type 1 diabetes and associated time in range outcomes
topic Diabetes
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354504/
https://www.ncbi.nlm.nih.gov/pubmed/35949359
http://dx.doi.org/10.17925/EE.2022.18.1.27
work_keys_str_mv AT nallicheriarmaan reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes
AT mahoneykatherinem reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes
AT gutowhannaa reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes
AT bellininatalie reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes
AT isaacsdiana reviewofautomatedinsulindeliverysystemsfortype1diabetesandassociatedtimeinrangeoutcomes